<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Progression of <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> depends on vascularization and <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> in a malignant tissue </plain></SENT>
<SENT sid="1" pm="."><plain>Among a whole range of proangiogenic factors, a vascular endothelial growth factor A (VEGF-A) plays a key role </plain></SENT>
<SENT sid="2" pm="."><plain>Blockade of VEGF may lead to regression of vascular network and inhibition of a <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>In the present time, bevacizumab has been introduced into wide clinical practice in therapy of <z:hpo ids='HP_0003002'>breast cancer</z:hpo>, <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> and recurrent high-grade <z:hpo ids='HP_0009733'>gliomas</z:hpo> (HGGs) </plain></SENT>
<SENT sid="4" pm="."><plain>Coadministration of antiangiogenic therapy with irinotecan may increase probability of the response to the treatment and prolong progression-free survival rate (PFS) </plain></SENT>
<SENT sid="5" pm="."><plain>Moreover, bevacizumab is well tolerated and significantly improves patient's quality of life </plain></SENT>
<SENT sid="6" pm="."><plain>However, in the case of <z:mp ids='MP_0009277'>brain tumors</z:mp>, the efficiency of such an approach is controversial </plain></SENT>
<SENT sid="7" pm="."><plain>The antiangiogenic therapy can slightly delay <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> and does not lead to complete recovery </plain></SENT>
<SENT sid="8" pm="."><plain>In addition, it contributes to enhanced <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell invasion into the <z:mpath ids='MPATH_458'>normal</z:mpath> brain </plain></SENT>
<SENT sid="9" pm="."><plain>The mechanisms of resistance include activation of alternative proangiogenic signaling pathways, of an invasive population of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells, metabolic change toward glycolysis and recruitment of myeloid bone marrow-derived cells to <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>Obviously, that anti-VEGF therapy as monotherapy was not effective against HGGs </plain></SENT>
<SENT sid="11" pm="."><plain>To enhance the antitumor treatment efficacy, it is necessary to develop a multi-target strategy to inhibit critical processes in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> progression such as <z:mpath ids='MPATH_177'>angiogenesis</z:mpath>, invasion, autophagy, metastatic spread, recruitment of bone marrow-derived endothelial cells and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> stem-like cells </plain></SENT>
<SENT sid="12" pm="."><plain>In addition, anti-VEGF antibodies have shown a promising result as a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-targeting vector for delivery therapeutic and diagnostic drugs in <z:mp ids='MP_0009277'>brain tumors</z:mp> </plain></SENT>
</text></document>